|
|
Gerald W. Dorn, Thomas Force
J Clin Invest. 2005;
115(3):527
doi:10.1172/JCI24178
Abstract |
Full text
| PDF
I
n broad terms, there are 3 types of cardiac hypertrophy: normal growth, growth induced by physical conditioning (i.e., physiologic hypertrophy), and growth induced by pathologic stimuli. Recent evidence suggests that normal and exercise-induced cardiac growth are regulated in large part by the growth hormone/IGF axis via signaling through the PI3K/Akt pathway. In contrast, pathological or reactive cardiac growth is triggered by autocrine and paracrine neurohormonal factors released during biomechanical stress that signal through the Gq/phospholipase C pathway, leading to an increase in cytosolic calcium and activation of PKC. Here we review recent developments in the area of these cardiotrophic kinases, highlighting the utility of animal models that are helping to identify molecular targets in the human condition.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(41)
| Title and authors |
Publication |
Year |
Scaffold-Based Transplantation ofAkt1-Overexpressing Skeletal Myoblasts: Functional Regeneration Is Associated with Angiogenesis and Reduced Infarction Size
Matthias Siepe, Peter Golsong, Annika Poppe, Britta Blumenthal, Robert von Wattenwyl, Claudia Heilmann, Katharina Förster, Christian Schlensak, Friedhelm Beyersdorf
|
Tissue Engineering Part A
|
2011 |
Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy
H. Cheng, M. Zheng, A. K. Peter, K. Kimura, X. Li, K. Ouyang, T. Shen, L. Cui, D. Frank, N. D. Dalton, Y. Gu, N. Frey, K. L. Peterson, S. M. Evans, K. U. Knowlton, F. Sheikh, J. Chen
|
Human Molecular Genetics
|
2011 |
Selective activation of PI3K /Akt/GSK-3 signalling and cardiac compensatory hypertrophy during recovery from heart failure
J. C. Braz, R. M. Gill, A. K. Corbly, B. D. Jones, N. Jin, C. J. Vlahos, Q. Wu, W. Shen
|
European Journal of Heart Failure
|
2009 |
CHF1/Hey2 promotes physiological hypertrophy in response to pressure overload through selective repression and activation of specific transcriptional pathways.
Man Yu, Yonggang Liu, Fan Xiang, Yuxin Li, Darragh Cullen, Ronglih Liao, Richard P Beyer, Theodor K Bammler, Michael T Chin
|
OMICS
|
2009 |
Regulation of phospholipase C in cardiac hypertrophy
Paramjit S Tappia, Tushi Singal
|
Clinical Lipidology
|
2009 |
Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling
G. W. Dorn
|
Cardiovascular Research
|
2008 |
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes
J. S. Martini, P. Raake, L. E. Vinge, B. R. DeGeorge, J. K. Chuprun, D. M. Harris, E. Gao, A. D. Eckhart, J. A. Pitcher, W. J. Koch
|
Proceedings of the National Academy of Sciences
|
2008 |
Genomics in cardiac metabolism
J.-L. Samuel, M. C. Schaub, M. Zaugg, M. Mamas, W. B. Dunn, B. Swynghedauw
|
Cardiovascular Research
|
2008 |
Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 and CREB
J. Feng, E. Lucchinetti, G. Fischer, M. Zhu, K. Zaugg, M. C. Schaub, M. Zaugg
|
Cardiovascular Research
|
2008 |
A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy
Kristina Lorenz, Joachim P Schmitt, Eva M Schmitteckert, Martin J Lohse
|
Nat Med
|
2008 |
|